How Ozempic Lowers Blood Glucose
Ozempic (semaglutide) is a GLP-1 receptor agonist that mimics the hormone glucagon-like peptide-1 (GLP-1). It activates GLP-1 receptors in the pancreas, gut, and brain to regulate glucose levels primarily in type 2 diabetes patients.[1]
Primary Mechanism: Boosting Insulin Secretion
Ozempic stimulates pancreatic beta cells to release more insulin in a glucose-dependent way. This means insulin secretion ramps up only when blood sugar is high, reducing hyperglycemia without causing dangerous hypoglycemia.[1][2]
Suppressing Glucagon Release
It inhibits glucagon secretion from pancreatic alpha cells, also in a glucose-dependent manner. Glucagon normally raises blood glucose by prompting liver glycogen breakdown; blocking it prevents excess glucose production during fasting or meals.[1][2]
Slowing Gastric Emptying
Ozempic delays stomach emptying, which slows carbohydrate absorption from food into the bloodstream. This blunts post-meal glucose spikes (postprandial hyperglycemia).[1][3]
Reducing Appetite and Food Intake
By acting on brain GLP-1 receptors, it signals satiety, lowering overall calorie and carb intake. This supports gradual weight loss, which improves insulin sensitivity and further aids glucose control.[1][2]
Effects on Insulin Sensitivity
Long-term use enhances insulin sensitivity in muscles and liver, partly through weight loss. It does not directly improve beta-cell function but preserves it over time.[2][3]
How These Combine for Glucose Control
The mechanisms work together: insulin rises and glucagon falls during meals for precise control, while slowed digestion and appetite reduction prevent overload. Clinical trials show A1C drops of 1-2% over 6-12 months, with greater effects in higher baseline glucose.[2]
Sources
[1]: Ozempic Prescribing Information (Novo Nordisk)
[2]: FDA Label for Ozempic
[3]: NEJM: Semaglutide Mechanism Review